MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,505K
EPS
-$0.14
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue from collaborations
-
-
0*
-
Revenue from customers
0
-
-
-
Revenue from licensing agreements
27,778
2,830
169*
741
Research and development
24,050
23,352
17,038
23,937
General and administrative
5,618
6,407
4,945
5,165
Total operating expenses
29,668
29,759
21,983
29,102
Loss from operations
-1,890
-26,929
-21,814
-28,361
Interest and other income, net
221
811
750
1,085
Change in fair value of 2023 common warrants
-2,976
-3,395
-1,213
4,205
Income (loss) before income tax
1,307
-22,723
-19,851
-31,481
Income tax provision
2,811
317
30
56
Net (loss) income
-1,504
-23,040
-19,881
-31,537
Unrealized loss on available-for-sale securities
-1
-30
18
35
Unrealized loss on pension plans
-
-
5
-
Other comprehensive loss
-1
-30
13
35
Comprehensive (loss) income
-1,505
-23,070
-19,868
-31,502
Basic EPS
-0.14
-2.21
-1.908
-3.04
Diluted EPS
-0.14
-2.21
-1.965
-3.04
Basic Average Shares
10,430,808
10,402,967
10,410,684
10,369,535
Diluted Average Shares
10,430,808
10,402,967
10,109,472
10,369,535
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive (loss) income
-$1,505K
(90.53%↑ Y/Y)
Change in fair value of
2023 common warrants
-$2,976K
(-76.93%↓ Y/Y)
Interest and other
income, net
$221K
(-81.69%↓ Y/Y)
Net (loss) income
-$1,504K
(90.52%↑ Y/Y)
Other comprehensive
loss
-$1K
(96.30%↑ Y/Y)
Income (loss) before
income tax
$1,307K
(108.34%↑ Y/Y)
Loss from operations
-$1,890K
(89.82%↑ Y/Y)
Revenue from licensing
agreements
$27,778K
(2778.55%↑ Y/Y)
Income tax provision
$2,811K
(1419.46%↑ Y/Y)
Unrealized loss on
available-for-sale securities
-$1K
(96.30%↑ Y/Y)
Total operating
expenses
$29,668K
(51.89%↑ Y/Y)
Research and development
$24,050K
(72.08%↑ Y/Y)
General and
administrative
$5,618K
(1.12%↑ Y/Y)
Buy us a coffee
Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, Inc. (ALGS)